MEDIPOST Co., Ltd. (KOSDAQ:078160)
South Korea · Delayed Price · Currency is KRW 8,790.00
-160.00 (-1.79%)
Sep 1, 2026, 3:30 PM KST
MEDIPOST Revenue
MEDIPOST had revenue of 18.78B KRW in the quarter ending June 30, 2026, with 5.32% growth. This brings the company's revenue in the last twelve months to 74.84B, up 3.70% year-over-year. In the year 2025, MEDIPOST had annual revenue of 73.66B with 4.25% growth.
Revenue (ttm)
74.84B
Revenue Growth
+3.70%
P/S Ratio
4.67
Revenue / Employee
232.43M
Employees
322
Market Cap
349.82B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 73.66B | 3.00B | 4.25% |
| Dec 31, 2024 | 70.66B | 2.01B | 2.93% |
| Dec 31, 2023 | 68.64B | 4.44B | 6.92% |
| Dec 31, 2022 | 64.20B | 9.34B | 17.03% |
| Dec 31, 2021 | 54.86B | 6.23B | 12.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Bioneer | 338.01B |
| Medy-Tox | 251.08B |
| GC Cell | 162.00B |
| HLB Therapeutics | 64.45B |
| SillaJen | 10.92B |
| GI Innovation | 5.63B |
| AbClon | 5.31B |
MEDIPOST News
- 3 months ago - Charles River (CRL) Partners with Medipost for Cell Therapy Advancements - GuruFocus
- 9 months ago - BDA Advises MEDIPOST on Growth Capital Raise - Benzinga